Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Merck
Boehringer Ingelheim
Johnson and Johnson
Dow

Last Updated: December 3, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Buparlisib


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Buparlisib?

Buparlisib is an investigational drug.

There have been 40 clinical trials for Buparlisib. The most recent clinical trial was a Phase 3 trial, which was initiated on October 3rd 2012.

The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).

There are five hundred and fifty-two US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for Buparlisib
TitleSponsorPhase
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCCAdlai Nortye Biopharma Co., Ltd.Phase 3
A Clinical Trial of Buparlisib and Ibrutinib in LymphomaJanssen Scientific Affairs, LLCPhase 1
A Clinical Trial of Buparlisib and Ibrutinib in LymphomaNovartis PharmaceuticalsPhase 1

See all Buparlisib clinical trials

Clinical Trial Summary for Buparlisib

Top disease conditions for Buparlisib
Top clinical trial sponsors for Buparlisib

See all Buparlisib clinical trials

US Patents for Buparlisib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Buparlisib ⤷  Try it Free Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try it Free
Buparlisib ⤷  Try it Free Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE) ⤷  Try it Free
Buparlisib ⤷  Try it Free Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) ⤷  Try it Free
Buparlisib ⤷  Try it Free Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Try it Free
Buparlisib ⤷  Try it Free Antibody drug conjugates Novartis AG (Basel, CH) ⤷  Try it Free
Buparlisib ⤷  Try it Free Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) ⤷  Try it Free
Buparlisib ⤷  Try it Free Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer Novartis AG (Basel, CH) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Buparlisib

Drugname Country Document Number Estimated Expiration Related US Patent
Buparlisib Australia AU2015231053 2034-03-21 ⤷  Try it Free
Buparlisib Brazil BR112016021620 2034-03-21 ⤷  Try it Free
Buparlisib Canada CA2943339 2034-03-21 ⤷  Try it Free
Buparlisib China CN106231900 2034-03-21 ⤷  Try it Free
Buparlisib Eurasian Patent Organization EA201691896 2034-03-21 ⤷  Try it Free
Buparlisib European Patent Office EP3119199 2034-03-21 ⤷  Try it Free
Buparlisib Israel IL247921 2034-03-21 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Merck
Boehringer Ingelheim
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.